TXMD News and Press, TherapeuticsMD Inc. From 10/03/22

TherapeuticsMD ( NASDAQ: TXMD ) has received a $7M private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company...

Maturity Date of Financing Agreement Extended to October 31, 2022, with the Ability to Extend to November 30, 2022, if Additional Capital is Raised TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading wom...

TherapeuticsMD ( NASDAQ: TXMD ) appointed Brian Bernick and Mark Glickman as interim co-CEO and co-principal executive officers. Bernick and Glickman succeed Hugh O’Dowd as CEO, the company said in a Sept. 12 press release. Prior to this appointment, Be...

- Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Gl...

TherapeuticsMD's birth control ring saw year-over-year growth of almost 100% in Q2. Although costs came down significantly, TXMD continued to report an operating loss. Management believes a resolution to its recent inventory headwinds along with government support will drive incre...

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q2 2022 Earnings Call Aug 15, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript

Viridian Therapeutics ( VRDN ) surged nearly 60% in Monday's midday trading, bolstered by the release of strong clinical data related to a potential treatment of Thyroid Eye Disease. In other news, TherapeuticsMD ( TXMD ) and SNDL ( SNDL ) jumped on strong quarterly reports....

Therapeutics MD ( NASDAQ: TXMD ) is trading 22% higher after the company posted a 24%rise in revenue, helped by strong sales of Annovera. The company posted Revenue of $28.6M, while Q2 GAAP EPS was $12.39. Vaginal ring Annovera net product revenue rose...

Gainers: Viridian Therapeutics VRDN +45% . TherapeuticsMD TXMD +21% . Unity Biotechnology UBX +21% . Brainstorm Cell Therapeutics BCLI +12% . Genprex GNPX +10% . Losers: IDEAYA Biosciences IDYA -33% . Apexigen ( APGN ) -15%...

TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Dou...